Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early recurrence of hepatocellular carcinoma after radical resection

Table 3 Univariate logistic regression analysis in hepatocellular carcinoma patients with early or non-early recurrence after resection

Factors	B	SE	Wald χ2	P value	HR	95%CI
Age (group)	1.486	0.391	14.422	0.000b	4.419	2.052, 9.513
AFP	1.076	0.328	10.744	0.001b	2.933	1.541, 5.582
BCLC stage			23.108	0.000b
BCLC stage 1	0.339	0.704	0.232	0.6300	1.403	0.353, 5.572
BCLC stage 2	1.409	0.776	3.297	0.069	4.091	0.894, 18.718
BCLC stage 3	2.565	0.806	10.128	0.001a	13.000	2.679, 63.093
CNLC stage			25.163	0.000b
CNLC stage 1	1.313	0.457	8.259	0.004b	3.716	1.518, 9.097
CNLC stage 1	2.309	0.501	21.218	0.000b	10.065	3.768, 26.883
MVI	1.567	0.358	19.181	0.000b	4.791	2.376, 9.658
Pathological satellite focus	1.263	0.513	6.066	0.014b	3.534	1.294, 9.653
Tumor size	0.125	0.046	7.278	0.007b	1.133	1.035, 1.241
Tumor numbers	0.912	0.394	5.352	0.021a	2.489	1.149, 5.388
Tumor boundary	1.790	0.350	26.187	0.000b	5.987	3.017, 11.882
Tumor capsule	0.581	0.247	5.549	0.018a	1.788	1.103, 2.900
Intratumoral hemorrhage	0.728	0.374	3.784	0.052	2.070	0.995, 4.308
Intratumoral necrosis	1.274	0.337	14.265	0.000b	3.577	1.846, 6.930
Portal vein tumor thrombus	2.232	0.778	8.230	0.004b	9.317	2.028, 42.801
Large vessel invasion	2.217	0.521	18.090	0.000b	9.183	3.305, 25.515
Nonperipheral washout	1.106	0.540	4.202	0.040a	3.022	1.050, 8.701
Peritumoral enhancement	1.055	0.444	5.638	0.018a	2.873	1.202, 6.864
HBP tumor SI/peritumoral SI	-0.035	0.012	8.688	0.003b	0.965	0.943, 0.988
HBP peritumoral low signal	1.856	0.464	16.035	0.000b	6.401	2.580, 15.882
Peritumoral delay enhancement	-1.795	0.518	12.017	0.001b	0.166	0.060, 0.458

^aP < 0.05.

^bP < 0.01.

HR: Hazard ratio; 95%CI: 95% confidence interval; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; CNLC: China liver cancer; MVI: Microvascular invasion; SI: Signal intensity; HBP: Hepatobiliary phase.